Specifically, the use of tofacitinib with iguratimob, a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD), demonstrated greater efficacy in reducing the expression of IL-1β as one of the markers of pyroptosis in TNF-α-stimulated FLSs from patients with RA [51]. The gene discussed is TNF; the disease is rheumatoid arthritis.